

## FDA/AACR Public Workshop on Clinical Trial End Points in Primary Brain Tumors

The Food and Drug Administration (FDA) and the American Association for Cancer Research (AACR), with co-sponsorship by the American Society of Clinical Oncology (ASCO), are holding a public workshop on end points for primary brain tumors. Issues identified in the workshop will be further discussed before the Oncologic Drugs Advisory Committee (ODAC) and thereafter will be detailed in FDA Guidance Documents.

**Date:** January 20, 2006

**Time:** 8:00 a.m. – 4:00 p.m.  
4:00 p.m. – 5:00 p.m. (Optional Session: NCI Research Priorities)

**Address:** North Bethesda Marriott Hotel & Conference Center  
5701 Marinelli Road  
North Bethesda, Maryland 20852  
Phone: (301) 822-9200  
Fax: (301) 822-9201  
Toll-Free: 1-800-859-8003

**Metro Access:** Closest Metro stop is **White Flint Metro Station** on the RED line. Hotel is approximately 1 block away walking West on Marinelli Road (across Rockville Pike/Rte 355).

**Registration:** No registration is required to attend the meeting. Seating will be available for 225 people on a first-come, first-served basis.

**For further information, contact:**

Linda Burbank, Office of Oncology Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993. Phone: 301-796-1335. Email: [burbank@cder.fda.gov](mailto:burbank@cder.fda.gov)